

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-466US1	Application No. 10/546,131
	Applicant Moya Caffrey et al.		
	Filing Date August 19, 2005	Group Art Unit 1621	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
SK	AA	3,464,998	09/02/1969	Krimmel			
	AB	3,471,491	10/07/1969	Venkatachala et al.			
	AC	4,349,552	09/14/1982	Takaya et al.			
	AD	4,751,292	06/14/1988	Fox			
	AE	US 2004/0236109	11/25/2004	Van Straten et al.			
	AF	US 2005/0090524	04/28/2005	Ford et al.			
	AG	6,949,539	09/27/2005	Alcaraz et al.			
	AH	7,129,246	10/31/2006	Alcaraz et al.			
	AI	US 2006/0247257	11/02/2006	Dixon			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
SK	AJ	BE 650919 A	07/23/1964	Belgium			English Abstract only	
	AK	DE 1943404 A	12/17/1970	Germany			English Abstract only	
	AL	EP 0002065	05/30/1979	Europe				
	AM	EP 0867436	09/30/1998	Europe			English Abstract only	
	AN	WO 95/04720	02/16/1995	WIPO				
	AO	WO 99/29660	06/17/1999	WIPO				
	AP	WO 99/29661	06/17/1999	WIPO				
	AQ	WO 99/18074	04/15/1999	WIPO				
	AR	WO 00/61569	10/19/2000	WIPO				
	AS	WO 01/42194	06/14/2001	WIPO				
	AT	WO 01/44170	06/21/2001	WIPO				
	AU	WO 02/096426	12/05/2002	WIPO				
	AV	WO 03/042191	05/22/2003	WIPO				

Examiner Signature S. Kumar	Date Considered 1/22/07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-466US1	Application No. 10/546,131
	Applicant Moya Caffrey et al.		
	Filing Date August 19, 2005	Group Art Unit 1621	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
86	AW	WO 03/080579	10/02/2003	WIPO				
	AX	WO 04/073704	09/02/2004	WIPO				
	AY	WO 04/105798	12/09/2004	WIPO				
	AZ	WO 04/105797	12/09/2004	WIPO				
	AAA	WO 04/105796	12/09/2004	WIPO				
	ABB	WO 05/014529	02/17/2005	WIPO				
	ACC	WO 05/025571	03/24/2005	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
86	ADD	Accession No. 2003:42109, CAS Registry No. 487064-48-2, <u>2003</u> .
	AEE	Alcaraz et al., "Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155, <u>2001</u> .
	AFF	Alcaraz et al., "Novel P2X7 Receptor Antagonists" <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4043-4046 (2003)
	AGG	Baxter et al., "Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> , 13:4047-4050 (2003)
	AHH	Bourrie et al., "SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties," <i>Eur. J. of Pharm.</i> , 456:123-131 (2002)
	AII	Costakis et al., "Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles", <i>Journal of Medicinal Chemistry</i> 14(12):1222-1223 (1971)
	AJJ	Dell'Antonio et al., "Antinociceptive effect of a new P _{2Z} /P2X7 antagonist, oxidized ATP, in arthritic rats", <i>Neuroscience Letters</i> 327:87-90 (2002)
	AKK	Di Virgilio et al., "Purinergic P2X ₇ -Receptor: A Pivotal Role in Inflammation and Immunomodulation", <i>Drug Development Research</i> 45:207-213 (1998)
	ALL	Ferrari et al., "Extracellular ATP Triggers IL-1 β Release by Activating the Purinergic P2Z Receptor of Human Macrophages", <i>J. Immunol.</i> 159:1451-1458 (1997)
	AMM	Ferrari et al., "Purinergic Modulation of Interleukin-1 β Release from Microglial Cells Stimulated with Bacterial Endotoxin", <i>J. Exp. Med.</i> 185(3):579-582 (1997)
	ANN	Henderson et al., "Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist", <i>Cytokine</i> 3(3):246-249 (1991)
	AOO	Ho et al., "Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[<i>ij</i>] quinoline as a VLA-4 Antagonist", <i>J. Org. Chem.</i> 65:6743-6748, page 6745, scheme 5, (27) (2000)
✓	APP	Humphreys et al., "Modulation of P2X ₇ nucleotide receptor expression by pro-and anti-inflammatory stimuli in THP-1 monocytes", <i>Journal of Leukocyte Biology</i> 64:265-273 (1998)

Examiner Signature S. Kumar	Date Considered 1/22/07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-466US1	Application No. 10/546,131
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Moya Caffrey et al.	
		Filing Date August 19, 2005	Group Art Unit 1621

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
SC	AQQ	Kadota et al., "Significance of IL-1 β and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)", <i>Clin Exp. Immunol.</i> 103:461-466 (1996)
	ARR	Khurana et al., "Clinical aspects of rheumatoid arthritis", <i>Pathophysiology</i> , Volume 12, Issue 3, Abstract (2005)
	ASS	Kirkham, "Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis", <i>Annals of the Rheumatic Diseases</i> , 50:395-400 (1991)
	ATT	Li et al., "Should atherosclerosis be considered a cancer of the vascular wall?" <i>Medical Hypotheses</i> , 64:694-698 (2005)
	AUU	Ottersness et al., "Possible Role of IL-1 in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions", <i>Agent Act</i> 39 (Suppl):109-120 (1993)
	AVV	Mackenzie et al., "Could rheumatoid arthritis have an infectious aetiology?" <i>Drug Discovery Today: Disease Mechanism</i> , Volume 2, Issue 3, Abstract (2005)
	AWW	Rains et al., "Sulfasalazine, A review of its Pharmacological Properties and Therapeutic Efficacy in the Treatment of Rheumatoid Arthritis", <i>Drugs</i> 50:137-156 (1995)
	AXX	Richards et al., "Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy," <i>Eur. J. of Medic. Chem.</i> , 41:950-969 (2006)
	AYY	Sakito et al., "Interleukin 1 β , Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy", <i>Respiration</i> 63:42-48 (1996)
	AZZ	Seventh International Symposium on Adenosine & Adenine Nucleotides: "Adenosin-und Purinrezeptoren als Targets neuer Arzneimittel", <i>Deutsche Apotheker Zeitung</i> 142(36):62-65 (2002)
	AAAA	STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, 14 April 2002
	ABBB	STN International, File REGISTRY, see RN 445032-09-7, 30 August 2002
	ACCC	STN International, File CHEMCATS, Accession no. 2001:48444, 14 May 2001, NS18552, 2-Quinolincarboxamide, N-(tricyclo[3.3.1.1.3,7]dec-1-ylmethyl), CAS Registry No. 313688-07-2
	ADDD	STN International, File REGISTRY, see RN 401622-10-4, 24 March 2002
	AEEE	van den Berg, "Lessons from animal models of osteoarthritis, <i>Curr. Opin. Rheumatol.</i> 13(5): 452-6 (2001)
✓	AFFF	Yu et al., "Inhibition of IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract of <i>Tripterygium wilfordii</i> Hook", <i>Gen. Pharmac.</i> 25(6):1115-1122 (1994)

Examiner Signature S. Kumar	Date Considered 1/22/07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	